Hepa-Merz

Hepa-Merz is a prescription‑only intravenous product that contains the amino‑acid derivative Ornithine Aspartate. It is marketed in the European Union as a hepatoprotective agent intended to support ammonia detoxification in patients with liver‑related disorders. The formulation is supplied for administration by healthcare professionals under medical supervision.

Hepa-Merz is used in clinical settings to manage conditions associated with elevated ammonia levels and impaired liver function.

- Treatment of hepatic encephalopathy in patients with acute or chronic liver disease. - Adjunct therapy for liver cirrhosis to improve metabolic balance. - Management of hyperammonemia resulting from urea‑cycle disorders. - Supportive care during acute decompensation of liver disease. - Used as part of a comprehensive regimen for patients awaiting liver transplantation.

Side effects of Hepa-Merz vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common: - Mild nausea or vomiting. - Transient headache. - Slight increase in serum bilirubin. - Temporary dizziness. - Local irritation at the infusion site. - Mild electrolyte imbalance.

Serious: - Severe allergic reaction (anaphylaxis). - Acute hypotension or shock. - Significant hepatic decompensation. - Persistent vomiting leading to dehydration. - Cardiac arrhythmia. - Renal impairment secondary to high ammonia levels.

When prescribing Hepa-Merz, clinicians should consider several precautionary measures to ensure patient safety.

- Verify liver function tests and ammonia levels before initiation. - Use only under supervision of a qualified healthcare professional. - Adjust infusion rate in patients with cardiovascular instability. - Monitor for signs of hypersensitivity during the first administration. - Caution in patients with renal insufficiency; assess renal function regularly. - Avoid use in pregnant or breastfeeding women unless clearly indicated. - Discontinue if severe adverse reactions occur.

Hepa-Merz may interact with other medications that affect ammonia metabolism or cardiovascular stability.

Avoid: - Concurrent use of high‑dose lactulose that may exacerbate electrolyte shifts. - Co‑administration with potent vasodilators that could worsen hypotension. - Simultaneous infusion of other nephrotoxic agents.

Use with caution: - Benzodiazepines, as altered hepatic function may increase sedation. - Diuretics, due to potential electrolyte disturbances. - Anticoagulants, because of possible changes in plasma protein binding.